The Exceptional Role of Clay Siegall in Cancer Treatment Research
Dr. Clay Siegall is globally recognized for his role in the cancer research community. He is the founder and CEO of Seattle Genetics. He has interests in targeted cancer therapies and drug development. Recently, Siegall achieved a remarkable milestone in his life when he led the company into developing antibody-drug conjugates (ADCs), which are used in cancer treatment. Dr. Siegall owns a blog on wordpress.com, the Clay Siegall blog.
Siegall keeps his followers updated on several issues ranging from scientific research, technology, and politics. He derives the information from the National Public Radio (NPR). In his recent posts, he posted news on Trump’s intention to ditch the 2015 clean power plan, which was signed in Paris. The agreement, which was signed by President Obama, aimed at reducing United State’s contribution to global warming.
Regarding scientific research, he posted an article concerning the breakthrough in the treatment of various problems such as endometriosis, fibroids and gynecologic cancer that affect the female reproductive system. This will be made real after scientists developed a device mimicking the human female reproductive system. Still, in the scientific research, he posted an article concerning a recently developed device that decodes human thoughts enabling paralyzed people to control their muscles.
About Clay Siegall
The Seattle Genetics boss is a zoology graduate from the University of Maryland. He is also a holder of a Ph.D. in genetics from the George Washington University. Over his career, he has received various awards for his tireless efforts in cancer treatment research. In 1995, he received the Pierce Award, and in 2002, he was given the Ernst and Young Entrepreneur Award of the Year of the Pacific Northwest.
Role in Cancer Research Community
Siegall’s role in cancer research cannot be underestimated. He is known for the development of ADCs, which are essential in cancer treatment. Moreover, he has devoted most of his time in research about a technology that can necessitate the monoclonal antibodies to deliver cell-killing agents to the cancerous cells.
Role at Seattle Genetics
Under his leadership, the company has achieved tremendous success. With over 20 years of experience in cancer research, Dr. Siegall has led the firm into several strategic licenses, which has seen the company raise over $ 300 million. Siegall also led the firm to various capital raising initiatives gaining over $675 million during the company’s first public offering.